Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thomas Güttler1, Matthias Dobbelstein2, Dirk Görlich1

  • 1Max-Planck-Institut für Multidisziplinäre Naturwissenschaften, Am Fassberg 11, D-37077 Göttingen, Deutschland.

Biospektrum : Zeitschrift Der Gesellschaft Fur Biologishe Chemie (GBCH) Und Der Vereinigung Fur Allgemeine Und Angewandte Mikrobiologie (VAAM)
|February 23, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.

Cell death & disease·2025
Same author

Nuclear pore passage of the HIV capsid is driven by its unusual surface amino acid composition.

Nature structural & molecular biology·2025
Same author

Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication.

Antiviral research·2025
Same author

Membrane-Permeable 5-Fluorodeoxyuridine Triphosphate Derivatives Inhibit the Proliferation of <i>Plasmodium falciparum</i>.

ACS infectious diseases·2025
Same author

The FG Phase-A Biomolecular Condensate That Governs Transport Through Nuclear Pores: 2025 Albert Lasker Basic Medical Research Award.

JAMA·2025
Same author

A nanobody specific to prefusion glycoprotein B neutralizes HSV-1 and HSV-2.

Nature·2025

Camelid VHH antibodies, or nanobodies, offer a cost-effective alternative to monoclonal antibodies for treating COVID-19. These nanobodies can be rapidly produced in microbes to meet global demand.

Area of Science:

  • Biotechnology
  • Immunology
  • Virology

Context:

  • Monoclonal antibodies are effective therapeutics but face production challenges during pandemics.
  • Current manufacturing of monoclonal immunoglobulins is expensive and difficult to scale.
  • The COVID-19 pandemic highlighted the need for scalable and affordable therapeutic options.

Purpose:

  • To develop novel nanobodies for neutralizing SARS-CoV-2 and its variants.
  • To explore the potential of camelid VHH antibodies as a scalable therapeutic solution.
  • To present progress in engineering nanobodies for infectious disease treatment.

Summary:

  • Camelid VHH antibodies (nanobodies) can be produced cost-efficiently in microbial systems like bacteria or yeast.

Related Experiment Videos

  • This contrasts with the expensive mammalian cell production required for monoclonal antibodies.
  • Research demonstrates the development of nanobodies with potent neutralizing activity against SARS-CoV-2 and its emerging variants.

    • Impact:

    • Nanobodies present a promising, scalable, and affordable alternative for COVID-19 treatment.
    • This approach could significantly improve global access to essential therapeutics during health crises.
    • The findings pave the way for rapid development of microbial-produced antibody therapeutics.